Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
(AVZO) SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics Announces FDA Clearance of IND Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific ADC
What potential revenue uplift and valuation impact could successful development of AVZO-103 have on AVZO’s stock price?
How does AVZO-103’s Nectin4/TROP2 bispecific ADC compare to existing ADCs and competitors in terms of efficacy, safety, and market positioning?
What are the anticipated clinical trial timelines and key milestones for AVZO-103 following IND clearance?
13 days ago